Biotech Stock Alert : SUNSHINE BIOPHARMA ( OTCBB:SBFM) Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, Adva-27a
Biotech Stock Alert : SUNSHINE BIOPHARMA ( OTCBB:SBFM) Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, Adva-27a
Today's alert is for biotech stock OTCBB:SBFM
Montreal, Quebec, Canada ---(WWW.investorstockalerts.com ) Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports recent progress which has enabled the Company to advance to the next phase of drug development, namely GMP manufacturing, IND-enabling studies and Phase I clinical trials in humans.
“We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing, and recent fund raising efforts,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.
While Adva-27a has proven very effective in its ability to kill various types of cancer cells, the compound’s most remarkable activity is against multidrug resistant cancer cells. The Company has previously reported that Adva-27a is particularly effective against Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The Company has also previously reported that Adva-27a has performed extremely well in a battery of preclinical tests. These tests have shown that:
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7
micromolar.
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
The initial indication for Adva-27a’s Phase I human trials will be multidrug resistant breast cancer for which there are little or no treatment options.
The Company has recently taken delivery of a new batch of Adva-27a from the Contract Manufacturing Organization (CMO) and now is proceeding to conduct a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity.
The Company has recently raised $460,000 through a private offering of its Common Stock, with proceeds being used for manufacturing and other activities in preparation for Phase I clinical trials.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Disclaimers: please read prior to investing!
Disclaimer /Disclosure : Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. We are neither licensed nor qualified to provide investment advice. The information contained in our publications should be viewed as commercial advertisement and is not intended to be investment advice. This publication is not provided to any particular individual with a view toward their investment circumstances. The information contained in our publications are not to be considered an offer to buy or sell securities. We distribute opinions, comments and information free of charge to individuals who wish to receive them. Our publications and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiles based solely on information contained in our publications. Individuals should assume that all information contained in these publications about profiled companies is not trust worthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some of all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. This site is currently compensated by companies featured in the stock alerts unless otherwise noted
This site and affiliates have been compensated in restricted 144 shares of SBFM for news publication .
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
To be removed or unsubscribe email as news@investorstockalerts.com